Your Global Leader in Stem Cell Market Research
In recent months, exosome start-up companies have been the recipients of approximately $386.2 million in investor funding. Clearly, investors are feeling favorable toward companies developing exosome products and there is a growing belief that the industry is poised for growth.
To date, four companies have dominated the exosome funding world. These companies are:
Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits.
In this article:
Exosomes play an important role in various cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.
Exosomes are commonly found in blood, urine, and saliva, among other fluids. Exosomes are also present in other body fluids, such as synovial fluid, amniotic fluid, semen, vaginal fluid, breast milk, and more.
It has been long known that stem cells have the potential to exert therapeutic effects, but it has only been recently recognized that exosomes play an important role how stem cells exert their cellular functions.
Recently, exosomes have been gaining momentum as a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients. Exosome companies are multiplying in number, with new market entrants popping up rapidly.
Interestingly, 25% of all exosome publications were released in the past year, which is providing new technologies to the marketplace for commercialization.
Over the past few years, the following companies have emerged as specialists in exosome technologies. These exosome companies include:
If you found this blog valuable, subscribe to BioInformant’s stem cell industry updates.
As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Know of other exosome companies that should be on this list? Add them in the comments below.
Exosome research is on the rise, fueled by an increasing recognition of the central role that exosomes play in intercellular (cell-to-cell) communication and transportation. As intracellular messengers, exosomes have the potential to mediate many of the therapeutics effects commonly associated with cells, with far fewer risks.
In this article:
For competitors within the exosome marketplace, it is vital to assess existing and future trends. One of the best tools for assessing scientific progress is to review rates of exosome research.
When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and Chinese authors take second place.[1]
When the term “exosome” is searched within scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author, with 37 articles, making her one of the global authorities on exosome research.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Gabrielsson+S%5BAuthor%5D+AND+exosome
When the term “extracellular vesicles” is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Prof. Giovanni Camussi. The company is also a market leader in terms of patents and translational programs.
Google Trend data also shows a clear linear increase in interest in exosome-related topics. To compete for dominance within this market, it is essential to identify trends as they begin to impact the marketplace, not after they are in full effect.
If you found this blog valuable, subscribe to BioInformant’s stem cell industry updates.
As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, we encourage you to join more than half a million loyal readers, including physicians, scientists, executives, and investors.
In your opinion how will the research into exosome characterization advance regenerative medicine? Share your thoughts in the comments section below.
Up Next: Explosion of Interest In Exosome Technologies And Companies Leading The Charge
Footnotes
[1] Search on PubMed.gov. Search Term: “exosome” or “exosomes”. Date of Search: December 1, 2017.
[2] Ncbi.nlm.nih.gov. (2017). “PLoS ONE” AND exosome – PubMed – NCBI. [online] Available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=%22PLoS+ONE%22+AND+exosome [Accessed 12 Nov. 2017].
[3] Ncbi.nlm.nih.gov. (2017). “J Biol Chem” AND exosome – PubMed – NCBI. [online] Available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=%22J+Biol+Chem%22+AND+exosome [Accessed 12 Nov. 2017].\
Editor’s Note: This post was originally published on October 11, 2018, and has been updated for quality and relevancy.
The market for stem cell exosomes is a fast-growth, high potential market. Currently in its early-stages, the market is readily posed for expansion. With a limited number of market competitors and few products in clinical-stage trials, the market is ripe for disruption by new competitors and new technologies. [Read more…]
SEOUL, South Korea, Sept. 12, 2018 — ExoCoBio Inc. announced that it recently raised about $27 million in its series B funding. Top tier Korean investors participated in this round, including Seven Tree Equity Partners, CSQUARED Global Asset Management, TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum Investment, GU Equity Partners, QUANTUM Ventures Korea, Platinum technology Investment.
[Read more…]
